


Seventh
Edition

Medical Pharmacology

*As per the latest
CBME Guidelines |*
Competency Based Undergraduate Curriculum
for the Indian Medical Graduate



Padmaja Udaykumar



Dedicated to Education

CBS Publishers & Distributors Pvt Ltd

Contents

<i>Preface to the Seventh Edition</i>	vii
<i>Competencies</i>	xvii
<i>Abbreviations</i>	xx

Unit I: General Pharmacology

1. Principles of Pharmacology, Evidence-based Medicine and Routes of Drug Administration	3	Dose Response Relationship	48
Historical Aspects	3	Drug Synergism and Antagonism	50
Terminology	4	Factors that Modify the Effects of Drugs	52
Sources of Drugs	5		
Drug Formulations and Dosage Forms	7	4. Adverse Drug Reactions, Pharmacovigilance and Drug Interactions	60
Routes of Drug Administration	9	Adverse Drug Reactions	60
Systemic Routes	10	Drug Allergy	61
Local/Topical Application	17	Treatment of Drug Overdosage	65
		Pharmacovigilance	65
2. Pharmacokinetics	18	Counterfeit Drugs	66
Transport of Drugs Across Biological Membranes	19	Drug Interactions	66
Absorption	20		
Bioavailability	23	5. Drug Nomenclature, Drug Development, Drug Regulations, Essential Medicines, Prescriptions and Related Topics	69
Equivalence	24	Drug Nomenclature	69
Distribution	25	Drug Development	69
Volume of Distribution (V)	27	Drug Information Sources	72
Biotransformation (Metabolism)	28	Pharmacoeconomics	73
Enzyme Induction	32	Chronopharmacology	73
Excretion	34	Essential Medicines	74
Clinical Pharmacokinetics	35	Rational Drug Use	74
Drug Dosage	37	P-drugs	75
Therapeutic Drug Monitoring	38	Drug Regulations	76
Methods of Prolonging Drug Action	38	Prescription Writing	76
3. Pharmacodynamics	40		
Mechanisms of Drug Action	40		
Receptor	42		

Unit II: Autonomic Nervous System

6. Adrenergic Agonists and Antagonists	81	Adrenergic Transmission	82
Overview	81	Adrenergic Drugs	84
Autonomic Innervation	81	Adrenaline	86
		Noncatecholamines	90

Vasopressors	92
Nasal Decongestants	93
α_2 Agonists	93
Bronchodilators and Uterine Relaxants (Selective β_2 Stimulants)	93
β_3 Agonist	94
Anorectic Agents (Anorexiant)	94
Catecholamine Reuptake Inhibitors	95
Adrenergic Antagonists	96
α Adrenergic Blocking Agents	96
Selective α_1 Blockers	97
α_2 Blocker	98
β -Adrenergic Blocking Agents	99
α - and β -Adrenergic Blockers	105
Drugs used in Treatment of Glaucoma	105

7. Cholinergic and Anticholinergic Drugs 109

Cholinergic Drugs	110
Cholinomimetic Alkaloids	112
Indirectly Acting Cholinergic Drugs	113
Anticholinergic Drugs	119
Atropine Substitutes	122

8. Skeletal Muscle Relaxants 127

Peripherally Acting Skeletal Muscle Relaxants	128
Directly Acting Muscle Relaxants	132
Centrally Acting Muscle Relaxants	133
Drugs used in the Treatment of Local Muscle Spasm	135

Unit III: Autacoids and Related Drugs

9. Drugs Modulating Autacoids 139

Histamine	139
Histamine Antagonists (Antihistamines)	141
5-HT Modulating Drugs	145
5-hydroxytryptamine	145
Ergot Alkaloids	147
Drugs Used in the Treatment of Migraine	148
Other Autacoids	149
Eicosanoids	150
Prostaglandins and Thromboxanes	150
Leukotrienes	152
Platelet Activating Factor	153

10. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) 154

Salicylates	155
Para-aminophenol Derivatives	161

Propionic Acid Derivatives	162
Acetic Acid Derivatives	163
Fenamates (Anthranilic Acid Derivatives)	163
Pyrazolone Derivatives	164
Oxicams (Enolic Acid Derivatives)	164
Preferential COX-2 Inhibitors	165
Selective COX-2 Inhibitors	167

11. Drugs Used in Rheumatoid Arthritis and Gout 169

Nonsteroidal Anti-inflammatory Drugs	169
Glucocorticoids	169
Disease Modifying Anti-rheumatic Drugs	170
Pharmacotherapy of Gout	172

Unit IV: Anaesthetics

12. Local Anaesthetics 179

Introduction	179
Chemistry	179
Actions	180
Adverse Effects	181
Individual Compounds	182
Uses of Local Anaesthetics	183

13. General Anaesthetics 187

Introduction	187
Stages of General Anaesthesia	187
Mechanism of Action of General Anaesthetics	187
Inhalational Anaesthetics	188
Individual Anaesthetics	189
Newer Anaesthetic	192
Intravenous Anaesthetics	192
Preanaesthetic Medication	196

Unit V: Central Nervous System

- 14. Sedative Hypnotics 201**
 Introduction 201
 Excitatory Neurotransmitters 201
 Inhibitory Neurotransmitters 202
 Sedative Hypnotics 202
 Benzodiazepines (BZDs) 203
 Newer Agents 209
 Barbiturates 210
 Miscellaneous 212
- 15. Antiepileptic Drugs 214**
 Types of Epilepsy 214
 Antiepileptics 215
 Phenytoin 216
 Phenobarbitone 219
 Carbamazepine 220
 Ethosuximide 221
 Valproic Acid 221
 Benzodiazepines 222
 Miscellaneous Drugs 222
 Newer Antiepileptics 222
 Clinical Pharmacology 224
- 16. Drugs used in Neurodegenerative Disorders—Parkinsonism and Alzheimer's Disease 227**
 Antiparkinsonian Drugs 227
 Dopamine Precursor 228
 Dopamine Receptor Agonists 229
 Drugs that Inhibit DA Metabolism 230
 Drugs that Release Dopamine 231
 Anticholinergics 231
 Drug-induced Extrapyrarnidal Reactions 232
 Drugs used in Alzheimer's Disease 232
- 17. Drugs used in Psychiatric Disorders: Antipsychotics and Antianxiety Agents 234**
 Antipsychotics (Neuroleptics) 235
 Chlorpromazine (CPZ) 236
 Individual Antipsychotics 239
 Newer Drugs 242
 Other Antipsychotics 242
 Antianxiety Drugs (Anxiolytics) 242
- 18. Antidepressants and Mood Stabilizers 244**
 Selective Serotonin Reuptake Inhibitors (SSRIs) 245
 Tricyclic Antidepressants 246
 Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) 248
 Atypical Antidepressants 249
 MAO Inhibitors 249
 Mood Stabilizers 251
- 19. Opioid Analgesics and Antagonists 254**
 Analgesics 254
 Opioid Analgesics 254
 Morphine 256
 Pethidine and its Derivatives 262
 Mixed Agonists and Antagonists 267
 Opioid Antagonists 268
- 20. Alcohols 270**
 Ethyl Alcohol (Ethanol) 270
 Methyl Alcohol (Methanol, Wood Alcohol) 273
- 21. CNS Stimulants and Drugs of Abuse 275**
 Respiratory Stimulants 275
 Psychomotor Stimulants 275
 Convulsants 276
 Nootropics 276
 Drugs of Abuse and Addiction 277

Unit VI: Drugs Acting on the Kidney

- 22. Diuretics and Antidiuretics 283**
 Physiology of Urine Formation 283
 Diuretics 284
 High Efficacy, High Ceiling or Loop Diuretics 285
 Thiazides and Thiazide-like Diuretics 288
 Potassium Sparing Diuretics 290
 Carbonic Anhydrase Inhibitors 292
 Osmotic Diuretics 293
 Newer Agents 294
 Antidiuretics 295

Unit VII: Blood

- 23. Drugs used in the Disorders of Coagulation** **301**
- Heparin 302
 - Direct Thrombin Inhibitors (DTI) 305
 - Oral Anticoagulants 305
 - Thrombolytics (Fibrinolytics) 309
 - Antifibrinolytics 310
 - Antiplatelet Drugs 312
 - Coagulants 315
 - Sclerosing Agents 316
 - Plasma Expanders 316

Unit VIII: Cardiovascular System

- 24. Renin—Angiotensin—Aldosterone System and other Vasoactive Peptides** **321**
- Angiotensin 321
 - Direct Renin Inhibitors 322
 - Angiotensin-Converting Enzyme Inhibitors 322
 - Angiotensin Receptor Blockers (ARBs) 325
 - Other Vasoactive Substances 327
- 25. Calcium Channel Blockers** **329**
- Calcium Channels 329
- 26. Antihypertensive Drugs and Drugs used in Shock** **335**
- Classification 335
 - Diuretics 335
 - Drugs Acting on Renin Angiotensin Aldosterone System 337
 - Sympatholytics 338
 - Calcium Channel Blockers 341
 - Vasodilators 342
 - Treatment of Hypertension 345
 - Pharmacotherapy of Shock 347
 - Intravenous Fluids 348
- 27. Treatment of Cardiac Failure and Pharmacology of Cardiac Glycosides** **351**
- Physiological Considerations 351
 - Drugs used in Congestive Cardiac Failure 353
 - Pharmacology of Cardiac Glycosides 357
- 28. Drugs used in Ischaemic Heart Disease** **362**
- Angina Pectoris 362
 - Antianginal Drugs 362
 - Nitrates 363
 - Calcium Channel Blockers 366
 - β -Blockers 367
 - Potassium Channel Openers 367
 - Pharmacotherapy of Angina 369
 - Drugs used in Myocardial Infarction 369
 - Treatment of Peripheral Vascular Diseases 371
 - Other Drugs 372
- 29. Antiarrhythmic Drugs** **374**
- Other Antiarrhythmics 382
- 30. Hypolipidaemic Drugs** **384**
- Hypolipidaemics 385
 - Drugs used in the Treatment of Obesity 392

Unit IX: Respiratory System

- 31. Drugs used in the Treatment of Bronchial Asthma, COPD and Cough** **395**
- Bronchial Asthma 395
 - Bronchodilators 396
 - Anti-inflammatory Drugs 401
 - Anti-IgE Antibody 405
 - Treatment of Asthma 405
 - Drugs used in Treatment of Cough 406

Unit X: Gastrointestinal Tract

- 32. Drugs used in Peptic Ulcer and GERD 413**
 Antacids 414
 H₂ Receptor Blockers 416
 Proton Pump Inhibitors 418
 Muscarinic Antagonist 421
 Ulcer Protectives 421
 Other Drugs 422
 Treatment of *H. pylori* Infection 422
- 33. Emetics, Antiemetics and Prokinetic Agents 424**
 Physiology of Vomiting 424
 Emetics 424
 Antiemetics 425
 Prokinetic Agents 428
- 34. Drugs for Constipation, Diarrhoea, Irritable Bowel Disease, Inflammatory Bowel Disorders, Biliary and Pancreatic Diseases 431**
 Laxatives 431
 Other Laxatives 434
 Enema 434
 Drugs used in the Treatment of Diarrhoea 435
 Irritable Bowel Syndrome 438
 Inflammatory Bowel Diseases 439
 Biliary Diseases 440
 Pancreatic Diseases 440

Unit XI: Drugs used in Haematological Disorders

- 35. Haematinics 443**
 Drugs used in Anemias 443
 Iron 443
 Vitamin B₁₂ and Folic Acid 446
 Haematopoietic Growth Factors 448

Unit XII: Drugs used in Endocrine Disorders

- 36. Hypothalamus and Anterior Pituitary Hormones 453**
 Hypothalamic Hormones 454
 Anterior Pituitary Hormones 456
- 37. Thyroid Hormones and Antithyroid Drugs 460**
 Thyroid Hormones 460
 Hyperthyroidism and Antithyroid Drugs 463
- 38. Corticosteroids 468**
 Glucocorticoids 468
 Pharmacokinetics 471
 Adverse Effects of Glucocorticoids 473
 Mineralocorticoids 477
 Inhibitors of Adrenal Steroids Synthesis 478
- 39. Estrogens, Progestins, Hormonal Contraceptives and Drugs used in Infertility 479**
 Physiological Considerations 479
 Estrogens 479
 Selective Estrogen Receptor Modulators (SERMs) and Anti-estrogens 481
 Estrogen Synthesis Inhibitors 483
 Progestins 484
 Antiprogestins and Progesterone Receptor Modulators 486
 Drugs Used in the Treatment of Menopausal Symptoms 487
 Hormonal Contraceptives 488
 Drugs for Infertility 494
 Drugs used in Erectile Dysfunction 495

- 40. Oxytocin and Drugs Acting on the Uterus** 496
 Uterine Stimulants 496
 Uterine Relaxants (Tocolytics) 498
- 41. Androgens and Anabolic Steroids** 500
 Physiological Considerations 500
 Anabolic Steroids 501
 Antiandrogens 502
 Male Contraceptives 503
- 42. Insulin and Oral Antidiabetic Drugs** 504
 Diabetes Mellitus 504
 Insulin 504
 Oral Antidiabetic Drugs 511
 Insulin Secretagogues 511
 Biguanides 514
 Thiazolidinediones (TZDs) 515
- α -Glucosidase Inhibitors 516
 Amylin Analogs 516
 SGLT-2 Inhibitors 517
 Treatment of Diabetes Mellitus 517
 Glucagon 518
- 43. Agents Affecting Bone Mineral Turnover and Osteoporosis** 519
 Calcium 519
 Phosphorus 520
 Parathyroid Hormone (Parathormone—PTH) 520
 Vitamin D 521
 Calcitonin 523
 Drugs used in the Disorders of Bone 523
 Agents used in the Prevention and Treatment of Osteoporosis 525
 Sports Medicine 525

Unit XIII: Chemotherapy

- 44. General Considerations** 531
 Resistance to Antimicrobial Agents 533
 Antibiotic Stewardship Program 535
 Combination of Antimicrobials 537
 Chemoprophylaxis 538
 Superinfection 539
- 45. Sulfonamides, Cotrimoxazole, Quinolones and Chemotherapy of Urinary Tract Infection** 544
 Sulfonamides 544
 Cotrimoxazole 546
 Nalidixic Acid 547
 Fluoroquinolones 548
 Chemotherapy of Urinary Tract Infection 552
- 46. Beta-Lactam Antibiotics** 554
 Penicillins 554
 Natural Penicillins 555
 Semisynthetic Penicillins 558
 Beta-lactamase Inhibitors 561
 Cephalosporins 562
 Carbapenems 566
 Carbacephems 567
 Monobactams 567
- 47. Broad-Spectrum Antibiotics** 569
 Tetracyclines 569
 Chloramphenicol 574
 Tigecycline 576
- 48. Aminoglycosides** 577
- 49. Macrolides and other Antibacterial Agents** 582
 Erythromycin 582
 Ketolides 585
 Miscellaneous Antibiotics 585
 Lincosamides 586
 Glycopeptide Antibiotics 586
 Polypeptide Antibiotics 588
 Other Antimicrobial Agents 588
 Drugs Used in the Treatment of Sexually Transmitted Diseases 591
- 50. Chemotherapy of Tuberculosis and Leprosy** 593
 Drugs used in Tuberculosis 593
 First-line Drugs 593
 Second-line Drugs 598
 Treatment of Tuberculosis 599
 Drugs used in the Treatment of Leprosy 601

51. Antifungal Drugs	605	Drugs used in Amoebiasis	645
Drugs Acting on Cell Membrane	605	Treatment of Pneumocystosis	649
Azoles	607	Treatment of Leishmaniasis	649
Allylamines	611	Treatment of Trypanosomiasis	650
Drugs Acting on Cell Wall	611		
Drugs Acting on Nucleus	612		
Other Topical Antifungal Agents	613		
52. Antiviral Drugs	614	55. Anthelmintics and Drugs used in Scabies and Pediculosis	651
Anti-herpes Virus Agents	615	Benzimidazoles	651
Drugs used in Cytomegalovirus (CMV) Infections	617	Pyrantel Pamoate	654
Anti-influenza Virus Agents	618	Piperazine Citrate	654
Anti-hepatitis Agents	619	Levamisole	654
Antirhinoviral Drug	620	Niclosamide	654
Other Antiviral Drugs	621	Praziquantel	655
Anti-retroviral Agents	621	Diethylcarbamazine (DEC)	655
Nucleoside And Nucleotide Reverse Transcriptase Inhibitors (NRTIs)	621	Ivermectin	656
Non-nucleoside Reverse Transcriptase Inhibitors	623	Drugs used in Scabies and Pediculosis	657
Protease Inhibitors (PI)	625	Pediculosis	658
Entry Inhibitors	626		
Integrase Inhibitors or Integrase Strand Transfer Inhibitors (INSTIs)	627	56. National Health Programmes	659
Pharmacotherapy of COVID-19	628	Universal Immunization Program	660
		Communicable Diseases	660
		National Nutrition Programmes	662
		Non-communicable Diseases	664
53. Antimalarial Drugs	631	57. Cancer Chemotherapy	666
Life Cycle of the Malaria Parasite	631	Common Adverse Effects to Anticancer Drugs	667
Chloroquine	632	Alkylating Agents	668
Quinine	636	Antimetabolites	671
Mefloquine	638	Natural and Semisynthetic Products	675
Halofantrine and Lumefantrine	638	Miscellaneous	678
Primaquine	638	Hormones in Cancer Chemotherapy	680
Folate Antagonists	640	Biological Response Modifiers	684
Chloroguanide (Proguanil)	641		
Atovaquone	641	58. Antiseptics and Disinfectants	685
Artemisinin and Derivatives	641	Acids	685
Antibiotics in Malaria	643	Alcohols	686
Malaria in Pregnancy	643	Aldehydes	686
		Surfactants	686
		Phenol Derivatives	687
		Halogens	688
		Oxidizing Agents	688
		Dyes	689
		Metallic Salts	689
54. Drugs used in Amoebiasis, Pneumocystosis, Leishmaniasis (Kala-Azar) and Trypanosomiasis	645		

Unit XIV: Immunopharmacology

59. Immunosuppressants, Management of Organ Transplant Rejection, Immunostimulants and Immunization	693	Management of Organ Transplant Rejection	696
Immunosuppressants	693	Immunostimulants	696
		Immunization	697

Unit XV: Toxicology

60. Heavy Metal Poisoning, Chelating Agents and Treatment of Common Poisoning, Common Stings and Bites	705	Food Poisoning	715
Heavy Metal Poisoning	705	Cardiopulmonary Resuscitation (CPR)	716
Chelating Agents	706		
Treatment of Common Poisoning	709	61. Occupational and Environmental Pesticides, Food Adulterants, Pollutants and Insect Repellents	717
General Management	711	Pesticides	717
Treatment of Common Stings and Bites	714	Food Adulterants	718
		Environmental Pollutants	719
		Insect Repellants	720

Unit XVI: Miscellaneous Topics

62. Dietary Supplements, Nutraceuticals, Vitamins, Herbal Medicines and Enzymes in Therapy	723	Drug Prescription and Lactation	736
Dietary Supplements and Nutraceuticals	723	Paediatric Pharmacology	736
Nutraceuticals	723	Geriatric Pharmacology	739
Vitamins	724	Pharmacokinetic Changes	740
Minerals	727	Pharmacodynamic Changes	741
Sodium	727	Administration of Drugs in Renal Diseases	742
Potassium	728	Drug Administration in Liver Diseases	743
Magnesium	728	Gene Therapy	743
Zinc	729	64. Drugs used in Skin Disorders	745
Manganese	729	Keratolytics	745
Herbal Medicines	730	Sunscreens	745
Enzymes in Therapy	732	Antimicrobials	746
		Glucocorticoids	746
63. Drug Administration in Special Situations: Pregnancy, Lactation, Paediatrics, Geriatrics, Renal and Hepatic Diseases	735	Drugs used in Acne	746
Drugs in Pregnancy	735	Drugs used in Psoriasis	747
		65. Drugs used in Ocular Diseases	749
		66. Important Drug Interactions	751

<i>Bibliography</i>	753
<i>Index</i>	755

Principles of Pharmacology, CHAPTER 1 Evidence-based Medicine and Routes of Drug Administration

Competency achievement: The student should be able to:

PH 1.1 Define and describe the principles of pharmacology and pharmacotherapeutics.¹

PH 1.2 Describe the basis of evidence-based medicine and therapeutic drug monitoring.²

Pharmacology is the science that deals with the study of drugs and their interaction with the living systems. The word pharmacology is derived from the Greek word—*Pharmacōn* meaning an active principle and *logos* meaning a discourse.

HISTORICAL ASPECTS

The useful and toxic effects of many plant and animal products were known to man since ancient times. In fact, there has been a quest for drugs and remedies since the existence of mankind itself.

In early days, there was a close relationship between religion and the treatment of diseases. The knowledge of the use of drugs often rested with the priest or holyman. Drugs were thought to be magical in their actions. Several cultures like the Chinese, Greek, Indian, Roman, Persian, European and many others contributed a great deal to the development of medicine in early times. The drug prescriptions included preparations from herbs, plants, animals and minerals. However, written information on remedies used in early times is lacking.

The Indian and the Chinese writings are amongst the oldest written material in

medicine. India's earliest pharmacological writings are from the 'Vedas'. Rigveda (3000 BC) has description of some medicines. An ancient Indian physician Charaka, and then, Sushruta and Vagbhata, described many herbal preparations included in '**Ayurveda**' (meaning the science of life). Indians practiced vaccination as early as 550 BC.

'**Pen Tsao**' the Chinese materia medica was written as early as 1700 BC and it contained classification of medicinal plants and some preparations of plants, metals and animals.

The Egyptian medical papyri (1600 BC) described several preparations. The largest of them, Ebers Papyrus lists some 800 preparations.

The Greeks studied the toxic effects of various plant extracts. Their contribution to the growth of modern medicine is significant. **Hippocrates** (460–377 BC), a Greek physician, studied the cause of disease and wrote on the ethics of medicine and recommended judicious use of drugs. Galen (130–201 BC), also a Greek physician, practiced in Rome and put forth a doctrine that diseases are due to an imbalance of fluids—blood, phlegm, black bile and yellow bile. He believed that drugs had some properties like warmth, coldness, dryness or humidity and also thought that it is beneficial to use a combination of drugs to obtain these effects.

In the Middle Ages, many herbal gardens were cultivated by the monasteries. **Paracelsus** the '**Grandfather of Pharmacology**' born in Switzerland was the son of a physician. He

Pharmacoeconomics deals with the cost, i.e. economic aspects of drugs used therapeutically.

Pharmacogenetics (and pharmacogenomics) is the science that deals with the study of genetic basis for variation in drug responses (see page 54).

Pharmacoepidemiology is the study of both the useful and adverse effects of drugs on large number of people.

Pharmacovigilance is related to the detection, assessment, understanding and prevention of adverse effects of drugs (see page 65).

Toxicology deals with the adverse effects of drugs and also the study of poisons, i.e. detection, prevention and treatment of poisoning (*Toxicon = poison in Greek*).

Chemotherapy is the use of drugs and chemicals for the treatment of infections. The term now also includes the use of chemical compounds to treat malignancies.

Essential medicines are those that satisfy the healthcare needs of majority of the population and should be available at all times in adequate amounts and in the appropriate dosage forms (see page 74) as defined by the WHO.

Orphan drugs are drugs to be used for prevention and treatment of rare diseases.


Pharmacopoeia is the official publication containing information on drugs (see page 72).

Pharmacy is the science of identification, compounding and dispensing of drugs. It also includes collection, isolation, purification, synthesis and standardization of medicinal substances.

Chronopharmacology is the science that involves the correlation of drug effects to the circadian rhythm to obtain optimum therapeutic effect and minimize the adverse effects, e.g. bronchospasm usually occurs at night. Blood pressure rises at dawn and dusk and is the lowest at midnight (see page 73). **Chronotherapy** is the administration of drugs to match the circadian rhythm. **Chronobiotics** are drugs that can be used to modify or reset the circadian rhythm. They find application mostly in conditions like sleep disorders and jet lag.

SOURCES OF DRUGS

The sources of drugs could be natural, or synthetic and biotechnology.






Fig. 3.9: Types of antagonism with examples

3. Antagonism at the Receptor Level

The antagonist binds to the receptor and inhibits the binding of the agonist to the receptor. Such antagonism may be reversible or irreversible.

Reversible or competitive antagonism: The agonist and antagonist compete for the same receptor. When a fixed concentration of an agonist is employed and the dose of the antagonist is progressively increased, the response to the agonist is progressively diminished. However, by increasing the concentration of the agonist, the antagonism can be overcome. It is thus reversible antagonism. The same maximal response can still be obtained by increasing the dose of the agonist. It is also called **surmountable** or **equilibrium type** of antagonism. This is the most common type of antagonism. Acetylcholine and atropine compete at muscarinic receptors. The antagonism can be overcome by increasing the concentration of acetylcholine at the receptor. Tubocurarine and acetylcholine compete for the nicotinic receptors at the neuromuscular junction. The dose response curve of the agonist shifts to the right (Fig. 3.10) in the presence of competitive antagonists.

Clinical significance: When an antagonist is used therapeutically, it should be borne in mind that the extent of inhibition brought about by a reversible antagonist depends on the concentration of the agonist. Therefore, the dose of the antagonist should be adjusted to get the optimum response, e.g. propranolol is used to block β adrenergic receptors. An increased amount of the endogenous agonists noradrenaline and adrenaline are released in stress and the dose of the antagonist (propranolol) needed would also be more in such situations.




Fig. 3.10: Dose response curves of an agonist: A in the absence of competitive antagonist; B, C and D in the presence of increasing doses of a reversible competitive antagonist

Irreversible antagonism: The antagonist binds by covalent bonds to the receptor and it binds so firmly that it dissociates very slowly or not at all. Thus it blocks the action of the agonist and the blockade cannot be overcome by increasing the dose of the agonist and hence it is irreversible antagonism. In this type of antagonism, the duration of action is usually long since the effect remains till the new receptors are synthesized, e.g. adrenaline and phenoxybenzamine at alpha adrenergic receptors. This antagonism is also called **non-equilibrium** type of antagonism.

There is progressive flattening of the dose response curve (Fig. 3.11).

4. Noncompetitive Antagonism

The antagonist blocks at the level of the receptor–effector linkage, i.e. at a different site beyond the receptor and not on the receptor. There is flattening as well as some rightward shift of the dose response curve (Fig. 3.12). For example, verapamil blocks the cardiac calcium channels and inhibits the entry of Ca^{++} during depolarisation. It thereby antagonises the effect of cardiac stimulants like isoprenaline and adrenaline. Since non-competitive antagonism is often confused with irreversible antagonism, they are compared in the table (below).

FACTORS THAT MODIFY THE EFFECTS OF DRUGS

The same dose of a drug can produce different degrees of response in different patients and even in the same patient under different situations. Various factors modify the response to a drug. They are:




Fig. 3.11: Dose response curves of an agonist A, in the absence of antagonist, B, C, and D in the presence of increasing doses of an irreversible antagonist




Fig. 3.12: Non-competitive antagonism—there is flattening as well as some rightward shift of DRC

1. Body weight: The recommended dose is calculated for medium built persons. For the obese and underweight persons, the dose has to be calculated individually. Though body surface area is a better parameter for more accurate calculation of the dose, it is inconvenient and hence not generally used.

COMPARE AND CONTRAST

Parameter	Irreversible antagonism	Non-competitive antagonism
Receptor binding	Yes	Not involved
Mode of action	Binding irreversible or very long lasting	Binding at a different site than receptor
Example	Phenoxybenzamine at α receptors	Verapamil at Ca^{++} channels
DRC	Progressive flattening	Flattening and rightward shift

Table 5.2: Important drug schedules

<i>Schedule</i>	<i>Features</i>	<i>Examples</i>
Schedule H drugs—to be sold under “prescription only”	<ul style="list-style-type: none"> Warning to be given on the label: Schedule H drug. Warning: To be sold on the prescription of registered medical practitioner only Symbol R_x should be printed prominently on the left hand top corner of the label If the drug is covered under Narcotic Drugs and Psychotropic Substances Act, symbol NR_x should be printed instead of R_x 	Acyclovir Alprazolam Amitriptyline Atenolol Azathioprine Bacampicillin Barbiturates
Schedule X: Psychotropic drugs	<ul style="list-style-type: none"> The rules for sale are same as for schedule X drugs The label should contain the warning: “Schedule X drug” Symbol X R_x in red letters on left hand top corner Warning: To be sold on prescription of a registered medical practitioner only Schedule X drugs should be stored under lock and key Drugs should not be dispensed more than once unless such an instruction is given in the prescription No substitute or alternative drug should be given The prescription should be in duplicate and a copy should be retained for at least 2 years On the cash bill, the purchaser’s signature should be taken. 	Antibiotics Amphetamine Barbiturates Methaqualone Glutethimide
NDCT-2019	Describes requirements and guidelines for new drug and clinical trials	
Other important drug schedules:		
Schedule C	Includes biological and special (intravenous) products Druggists require separate license for sale of these drugs	Insulin, adrenaline
Schedule E	Includes poisons and drugs under Ayurvedic, Siddha and Unani systems of medicine. It applies to the storage and sale of such drugs.	
Schedule F, F1	Include vaccines and sera	
Schedule G	For these drugs, label should have the warning—‘Caution: It is dangerous to take this preparation except under medical supervision’. Containers should be labelled in red bottles against white background	Ethosuximide; anticancer drugs like bleomycin; hormones antidiabetics like insulin, glibenclamide
Schedule S	Prescribes standards for cosmetics	

7. Blank space should be avoided between direction and the signature of the doctor. If blank space is present, it should be struck off to avoid misuse of the space to obtain drugs illegally.

PARTS OF THE PRESCRIPTION

1. Date of writing the prescription.
2. Address of the prescriber—preferably prescriptions are written on the letter pad

with doctor’s name and address printed at the top.

3. Name, age, sex and address of the patient.
4. Superscription—the symbol R_x meaning ‘take thou’ is also considered as an invocation to the Greek Gods of healing—Jupiter and Horus.
5. Drug name and strength. This is the body of the prescription—also called inscription. Abbreviations should never be used.

Adrenergic Agonists and Antagonists

OVERVIEW

The nervous system is divided into central and peripheral nervous systems (Fig. 6.1). The peripheral nervous system consists of autonomic and somatic nervous systems. The autonomic nervous system (ANS) is **not under voluntary control** and, therefore, was so named by Langley (*Autos* = self, *nomos* = governing—in Greek). The ANS innervates the **heart**, the **smooth muscles**, the **glands** and the **viscera** and controls the functions of these organs (Fig. 6.2).




Fig. 6.1: Nervous system

The centres for autonomic reflexes are present in the hypothalamus, medulla and spinal cord. Hypothalamus coordinates the autonomic activity.

The ANS consists of two major divisions—the **sympathetic** and the **parasympathetic** (Fig. 6.4). Most of the viscera have both sympathetic and parasympathetic innervation. *The two divisions have opposing effects and normally their effects are in a state of equilibrium.* The prime function of the sympathetic




Fig. 6.2: Structures under the control of autonomic nervous system

system is to help a person to adjust to stress and prepare the body for **fight or flight reactions**, while the parasympathetic mainly participates in **tissue building reactions**. Man can survive and remain alive without sympathetic system (if maintained stress-free) but not without parasympathetic.

AUTONOMIC INNERVATION

Like the somatic nervous system, autonomic innervation also has an afferent, a center and an efferent.

Autonomic afferents: The autonomic afferents (Fig. 6.3) are carried in visceral nerves through nonmyelinated fibres. For example, the parasympathetic afferents are carried by the 9th and 10th cranial nerves. The autonomic efferent innervation consists of a myelinated preganglionic fibre which synapses with the postganglionic fibre. The postganglionic fibre

Table 7.5: Salient features of atropine derivatives

<i>Derivative</i>	<i>Preparations and dose</i>	<i>Indications</i>	<i>Comments</i>
1. Homatropine	HOMIDE 1, 2% eye drops; 1–2 drops	For fundoscopy and in iritis to produce mydriasis, it also produces cycloplegia	Duration of mydriasis 1–3 days
2. Cyclopentolate	CYCLOMID 0.5, 1% eye drops; 1–2 drops	To produce cycloplegia	Mydriasis up to 24 hrs
3. Tropicamide	TROPICAMET, TROMIDE 0.5, 15% eye drops 1–2 drops	Mydriasis for fundoscopy	Mydriasis 3–6 hrs—shortest acting
4. Propranolol	PROBANTHINE 15 mg tab; 15–30 mg TDS	Peptic ulcer	Gastric emptying is delayed
5. Oxyphenonium	ANTRENYL 5, 10 mg tab; 5–10 mg	Peptic ulcer, GI hypermotility	Delays gastric emptying; NM blockade in higher dose
6. Clidinium	NORMAXIN 2.5 mg with dicyclomine 10 mg + chlordiazepoxide 5 mg; 2.5–5 mg oral	Peptic ulcer, colic, IBS	May be combined with BZD for dyspepsia
7. Glycopyrrrolate	PYROLATE 0.2 mg/ml, 1 ml amp, 10 ml vial; 0.1–0.3 mg IM; 1–2 mg oral	Preanaesthetic medication	Does not cross BBB – No CNS effects
8. Dicyclomine	CYCLOPAM 20 mg with paracetamol 500 mg; 20 mg/ml inj. 10–20 mg TDS	Motion sickness, morning sickness, antispasmodic in dysmenorrhoea, IBS	Also has antiemetic properties
9. Valtropium	EPIDOSIN 10 mg tab, 8 mg inj.; 10 mg oral, 8 mg IM	Spasmodic, dilatation of cervix	—
10. Oxybutynin	OXYSPASS, OXYBUTIN 2.5, 5 mg tab; 5 mg BD-TDS	Urinary disorders—to increase bladder holding capacity	Can also be instilled directly into bladder or applied transdermally
11. Tolterodine	TORQ 1, 2 mg tab; 2 mg BD	Urinary disorders—to reduce urinary urgency and frequency	Dose to be reduced in patients receiving microsomal enzyme inhibitors
12. Flavoxate	URISPAS 200 mg tab; 200 mg TDS	Urinary disorders—to reduce urinary urgency and frequency as in cystitis, urethritis and prostatitis	Also has local anesthetic and analgesic properties
13. Darifenacin	DARITEN 7.5 mg OD	Over active bladder	—
14. Benzhexol	ARTANE, PACITANE 2 mg tab; 2–12 mg/day	Drug-induced EPS	FDC with antipsychotics available
15. Ipratropium	IPRAVENT 20 µg and 40 µg/puff; 20–40 µg 3–4 times a day inhalation	COPD, bronchial asthma	More useful in COPD than asthma
16. Tiotropium	TIOVA 18 µg ROTACAPS; 18 µg OD	COPD, bronchial asthma	Longer acting than ipratropium

IBS: Irritable bowel syndrome FDC: Fixed dose combination

EPS: Extrapyramidal symptoms NIM: Neuromuscular

Skeletal Muscle Relaxants


Competency achievement: The student should be able to:

PH 1.15 Describe mechanism/s of action, types, doses, side effects, indications and contraindications of skeletal muscle relaxants.¹


Skeletal muscle relaxants (SMRs) are drugs that reduce the muscle tone either by acting peripherally at the neuromuscular junction (neuromuscular blockers) or centrally in the cerebrospinal axis or directly on the contractile mechanism. They reduce the spasticity in a variety of neurological conditions and are also useful in surgeries.

Skeletal muscle relaxants may be classified as given in Flowchart 8.1.

Structure of d-Tubocurarine



Flowchart 8.1: Classification of skeletal muscle relaxants



1. PERIPHERALLY ACTING SKELETAL MUSCLE RELAXANTS

Neuromuscular Blockers (NMB)

A. Competitive Blockers

d-Tubocurarine: Curare was used by the South American Indians as arrow poison for hunting wild animals because curare paralysed the animals. On extensive research, the active principle from curare, **tubocurarine** was identified.

d-Tubocurarine (d-Tc) is the dextrorotatory quaternary ammonium alkaloid obtained from the plant *Chondrodendron tomentosum* and plants of the *Strychnos* species (l-tubocurarine is less potent). Several synthetic agents have been developed. All these are quaternary ammonium compounds because of which they are not well absorbed, do not cross the BBB and are quickly excreted.

Mechanism of Action

Non-depolarising blockers bind to N_M nicotinic receptors (see Fig. 7.3, page 111) on the motor end plate and block the actions of acetylcholine by competitive blockade (Fig. 8.1). These compounds slowly dissociate from the receptors and transmission is gradually restored. Thus, the action of d-Tc is reversible. Increasing the concentration of the agonist acetylcholine at the NMJ also overcomes the blockade. This can be done by the administration of anticholinesterases like neostigmine.





Fig. 8.1: d-Tc molecules bind to nicotinic receptors and prevent the binding of ACh on these receptors

Pharmacological Actions

Skeletal muscle: On parenteral administration, tubocurarine initially causes muscular weakness followed by flaccid paralysis. Small muscles of the eyes and fingers are the first to be affected, followed by those of the limbs, neck and trunk. Later the intercostal muscles and finally the diaphragm are paralysed and respiration stops. Consciousness is not affected throughout. Recovery occurs in the reverse order, i.e. the diaphragm is the first to recover. The effect lasts for 30–60 minutes (Table 8.1).

Autonomic ganglia: In high doses tubocurarine can block autonomic ganglia and adrenal medulla resulting in hypotension.

Histamine release: Tubocurarine can cause histamine release from the mast cells leading to bronchospasm, increased tracheobronchial and gastric secretions. Histamine release also contributes to hypotension. Some of the other NMBs also release histamine. They release histamine by a direct effect on the mast cells.

Pharmacokinetics

Tubocurarine and other NMBs are quaternary ammonium compounds, hence not absorbed orally. They are given either IM or IV.

Adverse Reactions

1. Respiratory paralysis and prolonged apnea—patient should be given artificial ventilation. Neostigmine or edrophonium

Table 10.3: Properties of some commonly used NSAIDs

NSAID	Properties	Adverse effects	Uses
Aspirin	Analgesic, anti-inflammatory, rheumatic fever, rheumatoid, psoriatic and osteoarthritis, closure of PDA; to delay labor or antiplatelet activity in post-stroke and post-MI	Gastritis, nausea, allergic reactions, precipitation of bronchial asthma, nephrotoxicity, hepatotoxicity, Reye's syndrome, delayed onset of labour, salicylism	Antiplatelet activity even in low dose, good anti-inflammatory , analgesic, Uricosuric agent. Irreversible inhibitor of COX-1 and COX-2
Paracetamol	Fever, as analgesic in headache, backache, dysmenorrhoea, myalgia and other painful conditions	Less gastric irritant, large doses—hepatotoxicity (toxic metabolite N-acetylbenzoquinone-imine)	Good analgesic, antipyretic but weak anti-inflammatory (weak PG inhibition in the periphery). Antidote: n-acetylcysteine
Diclofenac	Chronic inflammatory conditions, rheumatoid arthritis, osteoarthritis, acute musculoskeletal pain and post-operative pain	Same as aspirin	Good concentration in synovial fluid , adverse effects milder; aceclofenac is longer acting and more gastric friendly
Ibuprofen, naproxen	Analgesic anti-inflammatory, and antipyretic, all actions milder than aspirin	Same as aspirin, but milder	Good analgesic, anti-inflammatory, antipyretic
Piroxicam	Arthritis, musculoskeletal pain	Same as aspirin, but milder gastric irritant.	Good analgesic, antipyretic anti-inflammatory. Longer acting—OD dose
Phenylbutazone	Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis	Same as aspirin, but more salt and water retention, more toxic than aspirin.	Salt and water retention, poor analgesic, antipyretic Not preferred
Indomethacin	Rheumatoid, psoriatic arthritis; good anti-inflammatory and antipyretic but toxicity is high	Toxicity high-peptic ulceration, oedema, agranulocytosis, hypothyroidism, insomnia, vertigo, optic neuritis, blurred vision, convulsions	Because of toxicity, it is withdrawn in many countries
Mephenamic acid	Dysmenorrhoea, myalgias	Gastric irritation, diarrhoea	Efficacy low, more toxic, contraindicated in children, used for short periods
Celecoxib	Good anti-inflammatory, analgesic, antipyretic	Higher risk of CV thrombotic events; Nausea, gastritis—milder, rashes, drowsiness, dizziness, nephrotoxicity, hepatotoxicity	Does not inhibit platelet aggregation, highly selective COX-2 inhibitor

of the risk of hepatotoxicity, nimesulide is **now banned** in most countries including India.

SELECTIVE COX-2 INHIBITORS


Coxibs

Though NSAIDs are extremely useful drugs, they are poorly tolerated particularly when

they are used for long periods. Gastric irritation is the common side effect which limits its use. Selective inhibition of COX-2 was found to be advantageous because COX-2 is involved in inflammation and COX-1 which is protective on gastroduodenal mucosa is spared (Fig. 10.2). Some of the older NSAIDs have relative selectivity for selective COX-2 (meloxicam) but

COMPARE AND CONTRAST*Aspirin and Celecoxib (nonselective and selective COX-2 inhibitors)*

Features	Aspirin	Celecoxib
Chemistry	Salicylic acid derivative	Sulfonamide derivative
COX inhibition	Non-selective (COX-1, COX-2)	Selective COX-2 inhibitor
Ulcerogenic effect on gastric mucosa	+++ (Significant)	+ (Mild)
t _{1/2}	Short (2–3 hours)	Long (6–12 hours)
Effect on platelet function	Inhibits platelet aggregation	Does not
Risk of Reye's syndrome in children	Present	Nil
Risk of thrombosis, atherogenesis	Nil	Present
Cardiovascular toxicity	No significant effect	Risk of MI
Cerebrovascular toxicity	No significant effect	Risk of stroke
Use in post-MI patients	Recommended	Contraindicated
Prominent action	Analgesic, antipyretic, anti-inflammatory	Analgesic, antipyretic, anti-inflammatory
PG synthesis	Inhibited	Inhibited

**Fig. 10.2:** Role of COX-1 and COX-2

highly selective COX-2 inhibitors with several times greater selectivity for COX-2 have been synthesized—like the coxibs—**celecoxib, parecoxib and etoricoxib**. These drugs have analgesic, anti-inflammatory and antipyretic effects like non-selective NSAIDs but with much less gastric ulcerogenic effects. They also do not inhibit platelet aggregation because COX-1 is involved in platelet function. However, many of the coxibs have been withdrawn due to the adverse effects.

Adverse Effects

Clinical studies have shown that use of selective COX-2 inhibitors increase the risk of cardiovascular and cerebrovascular

thrombotic events—**may increase the risk of myocardial infarction and stroke. Hence most of them (like rofecoxib) were withdrawn** from the market and the others are under supervision. They are indicated only in patients who cannot tolerate NSAIDs and are at a high risk of developing peptic ulcer.

Celecoxib

Celecoxib, a diaryl substituted compound is highly selective COX-2 (10–20 times) inhibitor. It has good anti-inflammatory, analgesic and antipyretic properties but does not affect platelet aggregation. In such indications too, they should be used in the minimum effective dose for a short period only.

CNS Stimulants and Drugs of Abuse

Competency achievement: The student should be able to:

PH 1.22 Describe drugs of abuse (dependence, addiction, stimulants, depressants, psychedelics, drugs used for criminal offences).¹

PH 1.23 Describe the process and mechanism of drug deaddiction.²

Drugs that have a predominantly stimulant effect on the CNS may be broadly divided into:

1. Respiratory stimulants

Doxapram, nikethamide

2. Psychomotor stimulants

Amphetamine, cocaine, methylxanthines

3. Convulsants

Leptazol, strychnine.

RESPIRATORY STIMULANTS

Respiratory stimulants are also called *analeptics*. These drugs stimulate respiration and are sometimes used to treat respiratory failure. Though they may bring about temporary improvement in respiration, the mortality is not reduced. They have a low safety margin and may produce convulsions. The availability of ventilators has reduced the need for analeptics.

Doxapram appears to act mainly on the brainstem and spinal cord and increase the activity of medullary respiratory and vasomotor centres. Doxapram in low doses can selectively stimulate respiration. Given intravenously as an infusion.

1–2 mg/kg/hr or 40–80 mg IM.

Adverse effects are nausea, cough, restlessness, muscle twitching, hypertension, tachycardia, arrhythmias and convulsions.

Uses

1. Doxapram is occasionally used IV as an analeptic in acute respiratory failure.
2. Apnoea in premature infants not responding to theophylline.

Nikethamide is not used because of the risk of convulsions.

PSYCHOMOTOR STIMULANTS

Amphetamine and **dextroamphetamine** are sympathomimetic drugs (*see* page 91).

Cocaine is a CNS stimulant, produces euphoria and is a drug of abuse (*see* page 182).

Methylxanthines

Caffeine, theophylline and theobromine are the naturally occurring xanthine alkaloids. The beverages—coffee contains caffeine; tea contains theophylline and caffeine; cocoa has caffeine and theobromine.

Actions

CNS: Caffeine and theophylline are CNS stimulants. They bring about an increase in mental alertness, a reduction of fatigue, produce a sense of well-being and improve motor activity and performance with a clearer flow of thought. Caffeine stimulates the respiratory centre. Higher doses produce irritability, nervousness, restlessness,

insomnia, excitement and headache. High doses can result in convulsions.

CVS: Methylxanthines increase the force of contraction of the myocardium and increase the heart rate and, therefore, increase the cardiac output. But, they also produce peripheral vasodilatation which tends to decrease the BP. The changes in BP are, therefore, not consistent. Caffeine causes vasoconstriction of cerebral blood vessels.

Kidneys: The xanthines have a diuretic effect and thereby increase the urine output.

Smooth muscle: Xanthines cause relaxation of smooth muscles especially the bronchial smooth muscle (see page 399).

Skeletal muscle: Xanthines enhance the power of muscle contraction and thereby increase the capacity to do muscular work by both a central stimulant effect and the peripheral actions.

GI tract: Xanthines increase the secretion of acid and pepsin in the stomach and are gastric irritants.

Pharmacokinetics

Methylxanthines are well absorbed orally, widely distributed and are extensively metabolised in the liver; $t_{1/2}$ 7–12 hr. In higher doses $t_{1/2}$ may be prolonged due to saturation of metabolizing enzymes. Premature infants have a longer $t_{1/2}$ of 24–36 hr.

Adverse Effects

Adverse effects include nervousness, insomnia, tremors, tachycardia, hypotension, arrhythmias, headache, gastritis, nausea, vomiting, epigastric pain and diuresis. High doses produce convulsions. Tolerance develops after sometime. Habituation to caffeine is common.

Uses

- i **Headache:** Because of the effect of caffeine on cerebral blood vessels, it is combined with ergotamine for the relief of migraine

headache. Caffeine is also combined with aspirin/paracetamol for the treatment of headache.

- ii. **Bronchial asthma:** Theophylline is used in the treatment of bronchial asthma.
- iii. **Apnoea in premature infants:** Episodes of prolonged apnoea (>15–20 sec) may be seen in premature infants which if too frequent may result in neurologic and other tissue damage due to hypoxia. When no primary cause can be detected, methylxanthines may be used orally or IV. Theophylline or caffeine may be used for 1–3 weeks to reduce the duration of episodes of apnoea which may be seen in premature babies.

CONVULSANTS

Strychnine is an alkaloid obtained from the seeds of *Nux vomica*. On administration, it produces tonic convulsions—opisthotonus followed by coma and death. It acts as a competitive antagonist of the inhibitory neurotransmitter glycine—mainly stimulates the spinal cord and in higher doses the entire nervous system. **Strychnine is of no therapeutic value.** Poisoning can be treated by IV diazepam or clonazepam. Ventilatory support may be needed. 1:1000 potassium permanganate solution or tannic acid 2% solution can be used to adsorb the alkaloid and prevent its absorption. All sensory stimuli produce exaggerated reflexes and should, therefore, be avoided.

Leptazol or pentylene tetrazol is a CNS stimulant. By a direct effect on the central neurons, it produces convulsions. It is mostly used as an experimental drug to induce convulsions. Poisoning with leptazol is treated with diazepam.

NOOTROPICS

Nootropics are drugs that improve memory and cognition. They are also called cognition enhancers.

Ranolazine is orally effective with a bioavailability of 30–50%. It prolongs QT interval and, therefore, should be avoided with other drugs that prolong QT interval. It can also cause weakness, postural hypotension, dizziness, headache and constipation.

Dose: 500 mg sustained release tablets BD. RANEXA 100, 500 mg tab.

Oxyphedrine acts by improving myocardial metabolism in hypoxia. However, its efficacy is yet to be proved.

PHARMACOTHERAPY OF ANGINA

Exertional Angina

Coronary angioplasty with insertion of a stent is the preferred treatment in presence of significant narrowing of the coronary arteries. Coronary artery surgery is done when there is severe narrowing. Pharmacotherapy may be an alternative in some patients.

Acute attack: Sublingual nitroglycerin is the drug of choice. If the pain does not subside in 5 minutes, repeat the dose. After the relief of pain, the tablet should be discarded.

Acute prophylaxis: Sublingual nitroglycerin given 15 minutes before an exertion (e.g. walking uphill) can prevent the attack. The prophylactic effect lasts for 30 minutes.

Chronic prophylaxis: Long-acting nitrates or β -blockers (preferred) or calcium channel blockers can be used. All are given orally. If one drug is not effective, a combination of drugs may be used.

Combination of Drugs in Angina

1. **Nitrates + β -blockers:** Very effective in exertional angina. Reflex tachycardia due to nitrates is countered by β -blockers. Ventricular dilatation due to β -blockers is opposed by nitrates.
2. **Nifedipine + β -blockers:** The antianginal effects are additive. Reflex tachycardia due to nifedipine is countered by β -blockers.
3. **Nitrates + CCBs:** Nitrates decrease preload, CCBs reduce afterload and the combination reduces cardiac workload.

4. **CCBs + β -blockers + nitrates:** If the angina is not controlled by 2 drug combinations, 3 drugs can be used. Nitrates reduce preload, CCBs reduce afterload while β -blockers decrease heart rate. This combination is useful in severe angina.

Vasospastic Angina

Nitroglycerin and nifedipine given sublingually and amlodipine are effective in preventing and treating vasospastic episodes.

Unstable Angina

Unstable angina includes:

- Patients with exertional angina developing angina **at rest**.
- Severe, prolonged anginal attacks without ECG evidence of MI.
- Angina developing after myocardial infarction.

Such patients with unstable angina are at a high risk of developing MI or sudden death and need hospitalisation and rigorous treatment for its prevention. The primary goal of treatment is to increase myocardial blood flow.

Drugs used in Unstable Angina

1. **Aspirin:** Platelet aggregation can occlude narrowed coronary arteries and can also release potent vasoconstrictors. Aspirin (75–300 mg daily) prevents platelet aggregation and thereby could prevent myocardial infarction.
2. **Heparin:** In high-risk patients, IV/SC heparin reduces pain.
3. **Nitrates:** Intravenous nitroglycerin reduces the cardiac workload and relieves pain.
4. **Other drugs:** β -adrenergic blockers like atenolol (50–100 mg daily) and; if they are contraindicated, calcium channel blockers like diltiazem and verapamil may be given. Glycoprotein receptor antagonists (abciximab, eptifibatide and tirofiban) inhibit the final steps of platelet aggregation and are being tried in unstable angina.




Fig. 28.4: Pathophysiology and sites of drug action in myocardial infarction

DRUGS USED IN MYOCARDIAL INFARCTION

Coronary heart disease is the most important cause of premature death, particularly in the developed countries.

Rupture of an atheromatous plaque in the coronary artery (Fig. 28.4) results in an occlusive thrombus leading to acute myocardial infarction. Symptoms include severe substernal pain radiating to the left shoulder, medial aspect of the left arm with nausea, vomiting, sweating, palpitation and shortness of breath. Patients appear pale and apprehensive. The process of infarction gradually develops (unless it is severe) over 6–8 hours after which there is cell death in the infarcted area. Timely intervention can reduce the extent of damage. Coronary angioplasty with a stent inserted to recanalise the coronary artery is the preferred option. The immediate objective of treatment is to limit the myocardial ischaemia and the consequent cell death. Drugs used are given below:

Immediate Treatment

1. **Analgesics and antianxiety drugs:** Pain due to myocardial ischaemia evokes anxiety and apprehension which result in sympathetic overactivity. This itself could prove deleterious to the heart. Hence a good analgesic, like morphine 10 mg or pethidine 50 mg, is given intravenously through an IV cannula. They relieve pain and thereby reduce anxiety. Hence the demerits of sympathetic overactivity are reduced. Diazepam may also be given to reduce anxiety and produce sedation.
2. **Thrombolytics:** Can limit the extent of damage and reduce mortality, if started at the onset of symptoms. They should be started at the earliest possible (within 6–12 hr). Streptokinase 1.5 million units infusion is given over 1 hour. Urokinase or alteplase may be given as alternatives as 15 mg bolus and 0.5 mg/kg over the next 90 minutes.

Anistreplase is a form of streptokinase which is convenient to use because it is long acting and, therefore, can be used as a single IV injection. Alteplase is expensive and hence is mostly reserved for patients in whom streptokinase cannot be used (see page 309).

Thrombolytics should be **started at the earliest possible** (within 6–12 hours) because they can limit the extent of damage and reduce mortality.

3. **Antiplatelet drugs:** 300 mg of soluble aspirin should be given orally immediately at the onset of symptoms. It reduces mortality and improves the effect of thrombolysis. Aspirin should be continued for long term (75–150 mg/day) even after the patient recovers from MI. Patients allergic to aspirin may be given oral clopidogrel.
4. **Anticoagulants:** Heparin may be given to prevent the extension of thrombus and also to prevent deep vein thrombosis.
5. **Oxygen:** High flow oxygen should be given by inhalation.

Hypolipidaemic Drugs

Competency achievement: The student should be able to:

PH 1.31 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in the management of dyslipidemias.¹

Hyperlipoproteinaemias (HPL) are conditions in which the concentration of cholesterol or triglyceride (TG) carrying lipoproteins in the plasma is elevated above normal (Table 30.1). Increase in lipoproteins can hasten the development of atherosclerosis and is a risk factor for myocardial infarction.

Lipids and proteins form complexes called lipoproteins and circulate in the blood vessels. There are four types of lipoproteins:

- Low density lipoproteins (LDL)
- High density lipoproteins (HDL)
- Very low density lipoproteins (VLDL)
- Chylomicrons.

LDL is the primary carrier of cholesterol while VLDL is of triglycerides. There are different pathways for the transport of endogenous and exogenous lipids (Fig. 30.1). In the exogenous pathway, cholesterol and triglycerides absorbed from the gut are transported as chylomicrons. They are hydrolysed to chylomicron remnants by the action of lipoprotein lipase (LPL) and free fatty acids

are released which are taken up by muscle and adipose tissue. The chylomicron remnants are transported to the liver.

In the endogenous pathway, cholesterol and triglycerides from the liver are carried as VLDL to the muscle and adipose tissue. Here the triglycerides in VLDL are hydrolysed and free fatty acids released. Thus intermediate density lipoprotein (IDL) and then LDL are formed by the action of lipoprotein lipase. Cells have LDL receptors and LDL is taken up into the cell. When the LDL plasma levels rise, LDL is taken up by the scavenger macrophages. In this process, they are oxidised and such LDL is atherogenic.

Excess cholesterol from the cells is transported to the liver for excretion by reverse cholesterol transport. High density lipoproteins (HDL) take part in this process. They also antagonise atherogenesis by other mechanisms including antiplatelet—aggregatory effect, anticoagulant and other effects. High density lipoproteins decrease the risk of coronary heart disease, are called protective lipoproteins and higher plasma levels of HDL are thus desirable.

Types of Hyperlipoproteinaemias

Based on the lipoprotein fraction that is elevated, lipoprotein disorders may be

Table 30.1: Plasma lipid levels (mg/dl)

	Total CH	LDL – CH	HDL – CH	TGs
Desirable	<200	<100	>40 (men), >50 (women)	<150
Borderline	200–239	130–159	–	150–199
High	>240	>160	>60	>200




Fig. 30.1: Endogenous and exogenous pathways of lipid transport

broadly grouped into primary and secondary hyperlipidaemias (Table 30.2). Secondary hyperlipidaemias may be secondary to an underlying disorder.


HYPOLIPIDAEMICS

Elevated plasma levels of LDL cholesterol and low levels of HDL cholesterol enhance the risk of CHD along with the other risk factors, viz. smoking, family history of coronary artery disease, male sex, metabolic

Table 30.2: Types of primary hyperlipoproteinaemias

Type	Disorder	Plasma lipids raised
I.	Familial LPL deficiency	C, TG
IIa.	Familial hypercholesterolaemia	C
IIb.	Polygenic hypercholesterolaemia	C
III.	Familial dysbetalipoproteinaemia	C, TG
IV.	Hypertriglyceridaemia	TG
V.	Familial combined hyperlipidaemia	C, TG

C: Cholesterol, TG: Triglycerides, LPL: Lipoprotein lipase



syndrome, diabetes mellitus and hypertension. Hence hypercholesterolaemia needs to be controlled.

Hypolipidaemics are drugs that lower plasma lipid levels in the body.

HMG-CoA Reductase Inhibitors (Statins)

Hydroxymethylglutaryl-CoA (HMG-CoA) is the rate-controlling enzyme in the biosynthesis of cholesterol.

General Considerations

Competency achievement: The student should be able to:

PH 1.42 Describe general principles of chemotherapy.¹

PH 1.43 Describe and discuss the rational use of antimicrobials including antibiotic stewardship program.²

Chemotherapy can be defined as the use of a chemical substance in infectious diseases to destroy microorganisms without damaging the host tissues.

Antibiotics are substances produced by microorganisms which suppress the growth of or destroy other microorganisms at low concentrations.

Pasteur and Joubert were the first to identify that microorganisms could destroy other microorganisms. **Paul Ehrlich** 'The **Father of Modern Chemotherapy**' coined the term 'chemotherapy'. He showed that certain dyes can destroy microbes and demonstrated that methylene blue can be used in malaria. He synthesized many arsenical compounds for the treatment of syphilis and sleeping sickness. Paul Ehrlich was awarded Nobel Prize for his work on chemotherapy. The evolution of chemotherapy can be studied in three periods.

- i. Pre-Ehrlich era—before 1891
- ii. The period of Paul Ehrlich
- iii. Post-Ehrlich era—after 1935

Domagk in 1935 demonstrated that prontosil, a sulfonamide dye, is effective in some infections. Domagk was awarded Nobel Prize for his work. **Sir Alexander Fleming** discovered penicillin in 1928. He was studying different variants of staphylococci and found

that a fungus was contaminating one of the culture plates. This fungus, *Penicillium notatum*, produced a substance which inhibited the growth of a variety of microorganisms. The substance was named Penicillin. It needed extensive research and purification for clinical use. In 1941, penicillin was first used therapeutically on a policeman. The discovery of penicillin is described as the beginning of the 'golden era' of antibiotics. In the last 60 years, several powerful antibiotics and their semisynthetic derivatives have been produced.

Many infectious diseases, which were earlier incurable, can now be treated with just a few doses of antimicrobial drugs. Thus the development of antimicrobial drugs is one of the important advances of modern medicine. In fact, antimicrobials are one of the most commonly prescribed drugs but are often the most over used or misused drugs.

Mechanisms of Action of Antimicrobials

The structure and composition of the bacterial cell differs from the mammalian cells in many aspects. This has made it possible to some extent to design antibacterials to act on such structures, enzymes, etc. to make them more selective to bacteria and less toxic to the human beings. Thus, antibiotics target different sites on the bacterial cell like:

1. **Cell wall:** Beta lactams and glycopeptides (vancomycin) inhibit the synthesis of bacterial cell wall. As a result, bacteria with

Classification

Based on the site of action

Antimicrobials may be classified (Fig. 44.1) as drugs that:

1. **Inhibit cell wall synthesis**
Penicillins, cephalosporins, carbapenems, monobactam, vancomycin, teicoplanin, bacitracin, cycloserine.
2. **Damage cell membranes**
(causing leakage of cell contents)
Polymyxins, amphotericin B, nystatin.
3. **Bind to ribosomes and inhibit protein synthesis**
50S—erythromycin, chloramphenicol, clindamycin, streptogramins, linezolid
30S—tetracyclines, aminoglycosides
4. **Inhibit DNA gyrase**
Fluoroquinolones
5. **Inhibit DNA function**
(↓DNA dependent RNA polymerase)
Rifampicin
6. **Interfere with metabolic steps**
(Antimetabolite action)
Sulfonamides, sulfones, trimethoprim, pyrimethamine

weak cell walls are formed which swell and burst due to difference in tonicity.

2. **Cell membrane:** Polymyxins alter the permeability of the cell membrane leading to leakage of cell contents followed by cell death. Amphotericin B causes leakage of fungal cell contents to damage the cell membrane leading to cell death.

3. **Protein synthesis:** Several antimicrobials act by interfering with the protein synthesis. The bacterial ribosome has a 50S and a 30S subunit and mammalian ribosome has 60S and 40S subunits which are involved in protein synthesis. Antimicrobials like amino glycosides, tetracyclines, chloramphenicol and macrolides bind to and interfere with the activity of 30S or 50S ribosomal subunits in the bacteria and thereby inhibit protein synthesis.

Antibacterials may interfere with nucleic acid synthesis either by inhibiting DNA or RNA polymerase (e.g. rifampicin) or by inhibiting the enzyme DNA gyrase (quinolones).

4. **Metabolic pathway:** Drugs like sulfonamides interfere with the metabolic pathway of the bacteria, block the enzymes involved in




Fig. 44.1: Classification of antimicrobials based on their mechanisms of action

Table 60.2: Some specific antidotes for drugs and chemicals

<i>Agent causing toxicity</i>	<i>Antidote</i>	<i>Dose</i>
1. Paracetamol	N-acetyl cysteine	Oral 140 mg/kg followed by 70 mg/kg every 4 hr, or IV 150 mg/kg infusion over 15 min repeated as required.
2. Morphine and other opioids	Naloxone	1–2 mg IV repeated every 10–15 minutes.
3. Heparin	Protamine Sulphate	1 mg IV for every 100 units of heparin.
4. Cyanide	Sodium nitrate + Sodium thiosulfate	10 ml of 3% solution IV 50 ml of 25% solution IV
5. Organophosphates	Atropine, Oximes	2 mg IV repeated every 10 minutes Pralidoxime 1 gram IV every 3–4 hr 3 doses
6. Theophylline, caffeine	Esmolol	25–50 µg/kg/min- IV
7. Atropine	Physostigmine	1–2 mg IV slowly (or SC) may be repeated if symptoms reappear
8. Curare and other non-depolarizing skeletal muscle relaxants	Neostigmine	2 mg IV repeated as required.
9. Copper	d-penicillamine	100 mg/kg/day orally in 4 divided doses for 3–7 days.
10. Iron	Desferrioxamine	15 mg/kg/hr IV (100 mg desferrioxamine binds 8.5 mg of iron)
11. Arsenic	Dimercaprol	Ist day 400–800 mg deep IM in divided doses; 2nd and 3rd day 200–400 mg; 4th day onwards 100–200 mg
12. Lead	Calcium disodium edetate	1 g in 250 ml saline infusion twice a day.
13. Streptokinase and other fibrinolytics	Epsilon amino caproic acid	5 g oral or IV followed by 1 g hrly till bleeding stops (Max 30 gm in 24 hr)
14. Insulin	Glucose	50 ml of 50% solution.
15. Digitalis	Digoxin specific antibody fragments	10 vials (DIGI FAB) empiric therapy or specific No. of vials = $\frac{\text{Total digoxin consumed}}{0.5}$
16. Methanol, ethylene glycol	Ethanol or Fomepizole	10% ethanol is given orally –0.7 mg/kg loading Dose: 0.15 ml/kg infusion. loading dose 15 mg/kg repeated every 12 hours.
17. Carbon monoxide	Oxygen	100% by high-flow non-rebreathing mask.
18. Nitrites	Methylene blue	0.1% solution slow IV in the dose of 1–2 mg/kg body weight.
19. Warfarin	Vitamin K ₁ oxide, fresh blood	10 mg IM followed by 5 mg 4 hrly As required.
20. Benzodiazepines	Flumazenil	0.2 mg IV repeated as required (Max. 3 mg)
21. Iodine	Sodium thiosulphate	1–5%, solution orally

- tracheal tube may be inserted. Patient should be put in lateral position.
- ii. If breathing is depressed, artificial ventilation should be given. Oxygen may be needed.

- iii. *Circulation:* Circulatory status should be assessed by pulse rate, blood pressure and urine output. Suitable IV fluids should be given. Generally 1 litre of normal saline with 1 litre of dextrose

Dietary Supplements, Nutraceuticals, Vitamins, Herbal Medicines and Enzymes in Therapy

Competency achievement: The student should be able to:
PH 1.61 Describe and discuss dietary supplements and nutraceuticals.¹

DIETARY SUPPLEMENTS AND NUTRACEUTICALS

Dietary supplements are given along with the diet as a pill, capsule, tablet or liquid. Dietary supplements are not meant to replace food but are to be used in addition to food for health maintenance. The supplements include vitamins, minerals, herbals, botanicals, amino acids, enzymes and also some substances that have not been proved as being essential but could be having a beneficial biological effect.

Examples:

- Vitamin D supplements in people who do not get sufficient exposure to ultraviolet light.
- Calcium supplements to reduce risk of osteoporotic fractures.
- Protein supplements in people recovering from chronic illness or injury.
- Amino acids individually or in combination. Taurine is a popular supplement claimed to improve sports performance.

- Glucosamine—used as a nutrient for cartilage in osteoarthritis of knee.
- Body building supplements like high protein drinks, branched chain amino acids, glutamine, arginine, essential fatty acids, and creatinine are used by those involved in body building, weight lifters and athletes to increase lean body mass.

NUTRACEUTICALS

A nutraceutical (also called bioceutical or superfood) is a pharmaceutical compound that could produce beneficial effects to the user. It is a food or fortified food product that supplements the diet and also assists in treating or preventing disease. The term "nutraceutical" was coined in 1989 by Stephen De Felice, founder and chairman of the Foundation for Innovation in Medicine.

Nutraceuticals based on their source:

- Plant—tomato, garlic
- Animal—shark liver oil, cod liver oil.
- Mineral—calcium, magnesium, phosphorus.
- Microorganism—bifido-bacterium, lacto-bacilli.

Compare and Contrast

Nutraceutical

Nutraceutical is used to prevent diseases

Referred to as health product

No license is needed to sell

No prescription is required for purchasing

Pharmaceutical

Pharmaceutical is used for prevention and treatment of diseases

Referred to as drug.

Requires a license from the regulatory body

Can be purchased only by prescription (except OTC drugs)

Uses: They may be used to improve health, delay the process of aging, prevent chronic disease, increase life expectancy or support the structure or function of the body.

Some Nutraceuticals

- Coenzyme Q10 or ubiquinone used as purified nutritional supplement is an antioxidant. It has been tried in hypertension, heart failure and IHD. An interesting application is in prevention of statin-induced myopathy. Coenzyme Q10 levels may be reduced on administration of statins which may have a role in myopathy
- *Flax seeds:* Prevent mammary, colon and rectal cancers. Reduces blood pressure in hypertensive patients, reduces risk of diabetes and coronary artery disease.
- *Spirulina* has an immunostimulant property, used in arthritis and for delaying aging process.
- *Bitter gourd* has a hypoglycemic effect. The extract of bitter gourd increases the rate of glycogen synthesis by 4–5 fold in liver.
- *Garlic* used in the treatment of hyperlipidemia
- *Turmeric (curcuminoids)* has antimicrobial and anti-inflammatory activity. Recent findings indicate that it also is an integrase enzyme inhibitor.
- *Tomato lycopenes* prevents prostate cancer.
- *Fenugreek* has a laxative, expectorant and demulcent property.

Thus diet rich in nutraceuticals, along with regular exercise, stress reduction and maintenance of healthy body weight, will maximize health and reduce disease risk.

VITAMINS

Vitamins are organic compounds essential for normal metabolism in the body. They are supplied by the diet. A balanced diet supplies adequate amounts of vitamins to fulfill the

daily requirement. The requirement is increased during periods of rapid growth, pregnancy and lactation. Vitamin deficiencies result in characteristic signs and symptoms.

Vitamins are grouped into fat-soluble and water-soluble vitamins (Table 62.1).

Fat-soluble Vitamins

Vitamin A

Vitamin A is present in the diet as retinol, dehydroretinol or as carotenoids. Carotenoids are pigments present in green yellow vegetables and fruits and are converted in the body to retinol.

Physiological functions: Vitamin A has an important role in dark adaptation. It is essential for the synthesis of rhodopsin, the photosensitive pigment of rods. Vitamin A is also essential for maintenance of the integrity of epithelial cells, for growth and cell-mediated immunity.

Signs and symptoms of deficiency: Xerophthalmia (dryness of eyes), Bitot's spots in the conjunctiva, night blindness, diarrhoea, dry and rough skin are seen in early stages. In the later stages, keratomalacia, perforation of the cornea, necrosis and blindness can occur.

Daily requirement 3000–5000 IU/day.

Uses: In the prophylaxis and treatment of vitamin A deficiency.

1. **Prophylaxis:** 3000–5000 IU/day in presence of increased requirement.
2. **Treatment:** 50,000–1,00,000 IU intramuscularly or orally for 1–3 days followed by oral supplementation.
3. **Acne:** Retinoic acid or synthetic analogs of vitamin A like tretinoin or isotretinoin are used.

Hypervitaminosis A: Since vitamin A is a fat-soluble vitamin, it accumulates in the body on prolonged administration. The symptoms are dry skin (hyperkeratosis), anorexia, fever, alopecia, anaemia, oedema, headache, skin ulcers and tenderness over the bones.

Medical Pharmacology

is the thoroughly revised, enlarged and updated edition of the popular text-book. The book retains its simplicity, lucidity and clarity of writing—the hallmark features well appreciated by the medical students as well as the teachers.

The textbook covers all the topics as per the latest CBME Guidelines | Competency Based Undergraduate Curriculum for the Indian Medical Graduate prescribed by Medical Council of India (now structured as National Medical Commission).

Besides being the 'must read' for undergraduate medical students, the text also caters to the needs of the candidates preparing for postgraduate entrance and other competitive examinations. Students and teachers of dental sciences, pharmacy, nursing and other paramedical courses will find it particularly useful just like the other editions.

Highlights of the Seventh Edition

- New features, flowcharts and diagrams, added to explain the recent concepts
- Text completely revised, re-cast and enlarged to accommodate the latest curriculum prescribed by MCI
- New topics prescribed under the CBME guidelines have been added at relevant positions in the text
- Flowcharts explain every important mechanism of action
- Boxes made more functional and useful to the reader
- Text revision and enlargements based on reviews and comments by superspecialists and subject experts
- Student-friendly format followed
- Text and tables focus on clinical relevance
- Many mnemonics throughout the book help memorizing
- COMPARE AND CONTRAST series makes the textbook complete in giving an analytic edge.

Padmaja Udaykumar MD

is Professor and Head, Department of Pharmacology, and Former Vice Dean, Father Muller Medical College, Mangalore, Karnataka. She has a keen interest in medical education with an experience in teaching of more than 30 years and has been on the boards of studies of many universities. She has published several literatures and this is the 22nd book in the series of textbooks meant for medical, dental, nursing, physiotherapy and pharmacy students. Her other publications brought out by CBSPD are Pharmacology Companion and Pharmacology for Pharmacy Students. She also has several research papers to her credit. She has rich experience in clinical pharmacology; conducted and coordinated several clinical trials; and has been advising clinicians on the appropriate and rational use of drugs.



CBS Publishers & Distributors Pvt Ltd
 481/100, Park Road, 24 Anand Road, Daryaganj, New Delhi 110 002, India
 E-mail: delhi@cbspd.com, cbspd@vishalmail.in, Website: www.cbspd.com
 New Delhi | Bengaluru | Chennai | Guwahati | Kolkata | Mumbai
 Hyderabad | Jaipur | Mysuru | Patna | Pune | Thiruvananthapuram



Get more to
 access online
 020 26494918

